Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 2, 2004 - Issue 2
Submit an article Journal homepage
12
Views
2
CrossRef citations to date
0
Altmetric
Review

Recent advances in the treatment of HIV/AIDS

Corklin R Steinhart Florida/Caribbean AIDS Education Training Center, Mercy Hospital, 3161 S. Miami Avenue no. 806, Miami, Florida, USA. [email protected]
Pages 197-211 | Published online: 10 Jan 2014

References

  • Palella, FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Out-patient Study Investigators. N Engl. J. Med. 3338,853–860 (1998).
  • Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280,1497–1503 (1998).
  • Mocroft A, Vella S, Befield TL, et al. Changing patterns of mortality across Europe in patients with HIV-1. EuroSIDA Study Group. Lancet 352, 1725–1730 (1998).
  • Porter K, Babiker AG, Darbyshire JH, et al. CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 362,1267–1274 (2003).
  • Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl. J. Med. 317(4), 185— 191 (1987).
  • •Initial clinical paper on the first FDA-approved antiretroviral medicine. It shows how far we have come in the treatment of HIV/AIDS.
  • Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus Type 1 (HIV) infection: a double-blind placebo-controlled trial. Ann. Intern. Med. 112(10), 727–737 (1990).
  • Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200-500 CD4 cells per cubic millimeter. North American HIV Working Party. N Engl. J. Med. 333,1662–1669 (1995).
  • Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246,1155–1188 (1989).
  • Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373,123–126 (1995).
  • Wong J, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIC despite prolonged suppresion of plasma viremia. Science 278, 1291–1295 (1997).
  • Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278,1295–1300 (1997).
  • Pomerantz RJ. Reservoirs of human immunodeficiency virus Type 1: the main obstacles to viral eradication. Clin. Infect. Dis. 34,91–97 (2002).
  • •"An understanding of these reservoirs for HIV-1 in the setting of virally suppressive HAART will be critical for the development of new approaches to induce HIV-1 remissions and for the exploration of the possibility of viral eradication in the future." [Excerpted from the abstract].
  • Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282,1627–1632 (1999).
  • CDC. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 47(RR-5), 1–41 (1998).
  • ••The first of the DHHS guidelines inwhich the principles underlying our approach to treatment were delineated.
  • Shapiro MF, Morton SC, McCaffrey DE Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 281(24), 2305–2315 (1999).
  • Kiahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J. Med 334, 701–706 (1996).
  • •First paper describing the importance of a physician's experience in treating patients with HIV infection that results in a better clinical outcome.
  • Hirsch MS. When and what antiretroviral therapy to start. Programs and abstracts of the 10th conference on retroviruses and opportunistic infections (2003) (Abstract 187).
  • Gathe J, Washington M, Mayberry C, Piot D. Single drug-HAART: proof of concept. Program and abstracts of the 43rd Annual ICAAC (2003) (Abstract H–845).
  • Pierone G, Mieras J, Kantor C, Bulgin-Coleman D, Shearer J, McCabe J. Lopinavir as sole therapy for HIV infection. Program and abstracts of the 9th European AIDS Conference. (2003) (Abstract F1/5).
  • Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J. Med 341(25), 1865–1873 (1999).
  • •Describes the Dupont-Merck 006 trial that first demonstrated the superiority of an NNRTI-based regimen over the classic PI-containing one.
  • van Leeuwen R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 17(7), 987–999 (2003).
  • Robbins G, Shafer R, Smeaton L, et al. Antiretroviral strategies in naive HIV+ patients: comparison of sequential 3-drug regimens (ACTG 384). X-Wth International AIDS Confirence. (2002) (Abstract Lb OR20a).
  • Gulick RI, Ribaudo HJ, Shikuma CM, et al. ACTG 5095: a comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection. Abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. (2003) (Abstract 41).
  • Gallant JE, Rodriguez A, Weinberg W, et al. Early non-response to tenofovir DF (TDF) and Abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) and ABC and 3TC: E5530009 unplanned interim analysis. 43rd Interscience Conference Antimicrob. Agents Chemother. (2003) (Abstract H–1722a).
  • Dear Healthcare Professional Letter. High rate of virologic failure in patients with HIV infection treated with a once-daily triple NRTI regimen containing didanosine, lamivudine and tenofovir. Gilead Sciences, Inc. (2003).
  • Papasawas E, Ortiz GM, Gross R, et al. Enhancement of human immunodeficiency virus type-1 specific CD4 and CD8 T-cell responses in chronically infected persons after temporary treatment interruption. J. Infect. Dis. 182,766–775 (2000).
  • Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after earlytreatment of acute infection. Nature 407(6803), 523–526 (2000).
  • •An often cited reference, regarding the use of a structured treatment interruption in recently infected HIV patients.
  • Youle M, Tyrer M, Fisher M, et al. Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen. J. Acquir. Immun. Defic. Syndr. 29(1), 58–61 (2002).
  • Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl. J. Med. 344(7), 472–480 (2001).
  • •• Provacative article that serves as background for Decks recent hypothesis of how to treat the ARV-experienced patient.
  • Lawrence J, Mayers D, Huppler Hullsiek K, et al. CPCRA 064: a randomized trial examining structured treatment interruption for patients failing therapy with multi-drug resistant HIV. Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. (2003) (Abstract 67).
  • Dybul M, Nies-Kraske E, Daucher M, et al A randomized, controlled trial of long cycle structured intermittent vs. continuous ARV therapy for chronic HIV infection. Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. (2003) (Abstract 681b).
  • Dybul M, Yoder C, Hidalgo B, et al. A randomized controlled trial of intermittent versus continuous HAART. Abstracts ofthe 8th Confirence on Retroviruses and Opportunistic Infections. (2001) (Abstract 364).
  • Lori F, Maserati R, Foli A, et al. Structured treatment interruptions to control HIV infection. Lancet 355, 287–288 (2000).
  • Katlama C, Dominguez S, Duvivier C, et al. Long-term benefit of treatment interruption in salvage therapy (GIGHAART ANRS 097). Abstracts of the 10th Confirence on Retroviruses and Opportunistic Infections. (2003) (Abstract 68).
  • Ruiz L, Gomez L, Domingo P, et al. A multi-center, randomized controlled clinical trial of continuous versus intermittent HAART guided by CD4+ T-cell counts and plasma HIV-1 RNA levels. Abstracts of the 10th Confirence on Retroviruses and Opportunistic Infections. (2003) (Abstract 65).
  • Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med 133(1), 21–30 (2000).
  • ••The 'classic' paper demonstrating that inthe treatment of HIV, at least 95% adherence is essential to achieve virologic success.
  • Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15,1181–1183 (2001).
  • Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin. Infict. Dis. 30\(Suppl. 2), S171-S176 (2000).
  • Maggiolo F, Migliorino M, Maserati R, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir. Ther. 6(4), 249–253 (2001).
  • Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination of emtricitabine, didansosine and efavirenz vs. continued PI-based HAART in HIV-infected adults with undetectable plasma HIV-RNA: 48 week results of a prospective randomized multicenter trial (alize-anrs 99). Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. (2003) (Abstract 551).
  • FuzeonTm (enfuvirtide). Prescribing Information. Roche Pharmaceuticals. (2003).
  • Lalezari JP, Henry K, O'Hearn M, et al. Enfiwirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J. Med 348(22), 2175–2185 (2003).
  • Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J. Med 348(22), 2186–2195 (2003).
  • Trottier B, Arasteh K, Henry K, et al. Durability of response to enfuvirtide through 48 weeks in the TORO trials. Program and Abstracts of the 43rd Interscience Conference Antimicrob. Agents Chemother. (2003) (Abstract H835).
  • Chen RY, Kilby JM, SAAG MS. Enfurvirtide. Expert Opin. Invesug Drugs 11(12), 1837–1843 (2002).
  • •Excellent overview of the first approved fusion inhibitor.
  • Hornberger JC, Witek J, Kilby JM, Covington M, Green J. Clinical prognosis and cost-effectiveness of enfuvirtide (ENF) in the United States. Program and Abstracts of the 43rd Interscience Conference on Antimicrob. Agents Chemother. (2003) (Abstract H837).
  • Montaner J, DeMasi R, Delehanty J, et al. Analysis of virological response of enfuvirtide in TORO: implications for patient management. Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment (2003) (Abstract 116).
  • ••Post-hoc analysis of the TORO trials,describing the patient characteristics of those likely to have the best response to T–20.
  • Lalezari JP, Bellos N, Richmond G, et al. Final analysis of T-1249-102: T-1249 retains potent short-term antiviral activity in patients who have failed a regimen containing enfuvirtide (ENF). Program and Abstracts of the 43rd Interscience Conference on Antimicrob. Agents Chemother (2003) (Abstract H444).
  • Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 Recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37(1), 113–128 (2003).
  • ••Essential reading for any HIV practitioner.Descibes in detail the mechanisms of drug resistance tests, and the latest guidelines for using antiretroviral drug resistance testing.
  • Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 267, 483–489 (1995).
  • •First described the dynamic nature of HIV replication, the emergence of viral mutations, and implications for antiretroviral therapy. A must read for the serious HIV treater.
  • Hirsch MS, Conway B, d'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 279, 1984–1991 (1998).
  • Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 13, F17—F21 (1999).
  • Zolopa AR, Shafer RW, Warford A, et al. HIV-genotypic resistance patterns predict response to saquinavir—ritonavir therapy in whom previous protese inhibitor therapy had failed. Ann. Intern. Med 131,813–821 (1999).
  • Kuritzkes DR, Sevin A, Young B, et al. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine—lamivudine—ritonavir: genotypic analysis of human immunodeficiency virus Type 1 isolates from AIDS clinical trial group protocol 315. ACTG Protocol 315 Team. J. Infect. Dis. 181,491–497 (2000).
  • Richman DD, Bozzette S, Morton S, et al. The prevalence of antiretroviral drug resistance in the US. Program and abstracts of the 41st Interscience Conference on Antimicrob. Agents Chemother. (2001) (Abstract LB–17).
  • Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J. Med 347(6), 385–394 (2002).
  • •The lead article in the N. Eng. J. Med describing the problem of the prevalence of transmitted HIV drug-resistant virus.
  • Wensing AMJ, Van de Vijer DMAC, Asjo B, et al. Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10% of the patients carry primary drug resistance: the CATCH study. Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. (2003) (Abstract LB1).
  • Whitcomb JM, Parkin NT, Chappey C, Hellman NS, Petropoulis CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus Type 1 clinical isolates. J. Infect. Dis. 188,992–1000 (2003).
  • Durant J, Clevenbergh P, Halfon P, et al. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353,2195–2199 (1999).
  • •First paper showing the short-term usefulness of ARV drug resistance testing.
  • Meynard J-L, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for chossing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16,727–736 (2002).
  • Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16(4), 579–588 (2002).
  • Baxter J, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14, F 83—F 93 (2000).
  • Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16(2), 209–218 (2002).
  • Badri SM, Adeyemi OM, Max BE, Zagorski BM, Barker DE. How does expert advice impact genotypic resistance testing in clinical practice? CID 37, 708–713 (2003).
  • Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann. Intern. Med. 134(6), 440–450 (2001).
  • Sax PE, Islam R, Losina, Weinstein MC, Cohen CJ, Freedberg KA. Should resistance testing be done in antiretroviral-naive patients? A cost effectiveness analysis. Program and abstracts of the XIV International AIDS Conference (2002) (Abstract MoPeB3129).
  • LaBonte J, Lebbos J, Kirkpatrick E Enfuvirtide. Nature Rev. Drug Discovery 2, 345–346 (2003).
  • Trauger RJ, Ferre F, Daigle AE, et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus Type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA and percentage of CD4 cells. J. Infect. Dis. 169,1256–1264 (1994).
  • Kahn JO, Cherng DW, Mayer K, et al, for the 806 Investigator Team. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 3 10(6)/L CD4 cell counts: a randomized controlled trial. JAMA 284,2193–2202 (2000).
  • J J Rossi, N-S Leel, M Li 1, et al. Designing RNA I-based therapeutic strategies for HIV Programs and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections (2003) (Abstract 50).

Websites

  • The United Nations AIDS website. (Accessed March 2004) www.UNAIDS.org
  • The World Health Report 2002. World Health Organization. (Accessed March 2004) www.WHO.int/whr/2002/en.
  • Global Health-Sector Strategy for HIV/AIDS: 2003–2007. Department of HIV/AIDS. Family and Community Health. World Health Organization. (Accessed March 2004) www.who.int/en/
  • HIV/AIDS among African Americans. CDC. National Center for HIV, STD and TB Prevention Divisions of HIV/AIDS Prevention. (Accessed March 2004) www.cdc.gov/hiv/pubs/Facts/afam.htm
  • US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Accessed March 2004) http://aidsinfo.nih.gov/guidelines
  • Cheever L. Forum for Collaborative HIV Research. What do we know about adherence levels in different populations? Adherence to HIV therapy: building a bridge to success. (Accessed March 2004) http://www.gwhealthpolicy.org.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.